Navigation Links
18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkin's Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
Date:9/15/2009

SEATTLE, Sept. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today released updated 18-month follow-up clinical data for its phase III EXTEND (PIX 301) trial of pixantrone (BBR2778) for patients with advanced, relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL). Responses were evaluated by an Independent Assessment Panel that was blinded to patient assignment.

The table below shows the primary end of treatment data analyses previously reported and the new updated 18 month efficacy data analyses. This data is part of CTI's presentation today at the BioCentury NewsMakers conference at 10:30 AM ET.

                 End of Treatment      18 Month Follow-Up
                 ----------------      ------------------
                 CR/CRu                CR/CRu
                 ----------------      ------------------
    Pixantrone   20.0%                 25.7%
    Control       5.7%                  7.1%
    P Value       0.021                 0.005

                 ORR                   ORR
                 ----------------      ------------------
    Pixantrone   37.1%                 40.0%
    Control      14.3%                 14.3%
    P Value       0.003                 0.001

                 End of Treatment      18 Month Follow-Up
                 ----------------      ------------------
                 Progression Free      Progression Free
                 Survival              Survival
                 ----------------      ------------------
    Pixantrone   4.7 months            5.6 months
    Control      2.6 months            2.6 months
    P Value      0.007 (HR = 0.60)     0.002 (HR = 0.56)

                 Median Overall        Median Overall
                 Survival              Survival
                 ----------------      ------------------
    Pixantrone   8.1 months            10.2 month
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
2. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
3. Alimera Sciences Announces Presentation of Data From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study at ARVO 2009 Annual Meeting
4. MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up
5. Medgenics Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients
6. Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
7. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
8. Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months
9. Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death
10. Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
11. 12-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... -- Medela announced today that it has reached a five-year ... the exclusive distributor of the ABC Enteral Feeding Pump ... Pump. Through this agreement, Medela will be in a ... by offering a comprehensive set of products and programs. ... to the delivery of human milk to at-risk infants. ...
(Date:9/23/2014)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), ... commercialization of innovative therapeutics addressing cancer and other unmet ... focus on China , announces the ... and Chief Executive Officer of Spectrum Pharmaceuticals, Inc. to ... connection with the recently announced acquisition of greater ...
(Date:9/23/2014)... CARLOS, Calif. , Sept. 23, 2014 /PRNewswire/ ... company, today confirmed the initiation of human safety ... forms of addiction. A single dose of 18-MC, ... safety study conducted by Savant,s South American partner, ... experimental drug. Savant HWP plans to develop 18-MC ...
Breaking Medicine Technology:Medela Enters Exclusive Enteral Feeding Pump Agreement with Atlanta Biomedical Company 2CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 2CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 3CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 4Savant HWP Confirms Initiation of a Human Safety Trial for 18-MC, a Potential Anti-Addiction Therapy 2Savant HWP Confirms Initiation of a Human Safety Trial for 18-MC, a Potential Anti-Addiction Therapy 3
... , SAN DIEGO, Nov. 6 Ardea Biosciences, Inc. ... the development of small-molecule therapeutics for the treatment of ... recent accomplishments and financial results for the third quarter ... (Logo: http://www.newscom.com/cgi-bin/prnh/20091104/ARDEALOGO ) , "Since our last ...
... Inc., in collaboration with scientists at the Centers for Disease ... of Hong Kong, announced today the publication of two articles ... studies suggest that DAS181 (Fludase ® ) may play a ... Pandemic Influenza A(H1N1) and drug-resistant influenza. , DAS181 is ...
Cached Medicine Technology:Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 2Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 3Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 4Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 5Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 6Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 7Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 8NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 2NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 3NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 4
(Date:9/23/2014)... Randy Dotinga HealthDay Reporter ... cholesterol-lowering drugs while in the hospital for a hemorrhagic stroke ... than four times more likely to survive than people who ... People taking the commonly used drugs known as statins were ... to a rehabilitation facility, the study reports. When it ...
(Date:9/23/2014)... have published the first study to extensively characterize ... The Journal of Allergy and Clinical Immunology , ... has high levels of eosinophils in the blood ... mechanisms and has a gene expression pattern (transcriptome) ... disorder, eosinophilic esophagitis (EoE). , Eosinophilic gastrointestinal ...
(Date:9/23/2014)... and a researcher in UTSA,s South Texas Center for ... Ruhr University in Bochum, Germany to understand how humans ... week in an article published by the Proceedings ... is an acute infection caused by ingestion of food ... Vibrio cholerae . An estimated three to five million ...
(Date:9/23/2014)... a potential source of student diversity for medical ... however, there are significant challenges to enhancing the ... medical schools. The authors recommend that medical school ... be more inclusive of community college students. , ... Francisco and San Jose City College found that, ...
(Date:9/23/2014)... Affordable Care Act "Obamacare" was signed into ... the U.S. healthcare system since the 1960s. Designed to ... widely decried as an unwarranted intrusion into the affairs ... comparative study of healthcare systems in six Western countries, ... , supports a move away from privatized medicine toward ...
Breaking Medicine News(10 mins):Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 2Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 3Health News:Advancing the understanding of an understudied food allergy disorder 2Health News:Advancing the understanding of an understudied food allergy disorder 3Health News:UTSA microbiologists discover regulatory thermometer that controls cholera 2Health News:Medical students who attended community college likelier to serve poor communities 2Health News:Life, liberty, and the pursuit of healthcare? 2
... disorders may be round the corner as scientists have traced the ... To start with they have experimented on the rat brain and ... first time that such advances have been made vis-à-vis eating disorders. ... sets of brain cells respond to hormones, among them two proteins ...
... cancer center, New Orleans have identified and isolated a protein ... cancer to the liver. The protein, called Pa 28 alpha, ... lead investigator Justinian Ngaiza, a clinical fellow in hematology/oncology at ... To isolate the protein, Ngaiza and colleagues took ...
... that would alter the lives of millions, scientists at the ... simple method of administering protein based drugs such as insulin ... manufacture of tiny protein coated micro crystals can pass through ... powder inhalers similar to those used by asthma sufferers.// ...
... herpes virus that causes infectious mononucleosis, Epstein-Barr virus (EBV), has ... disease. But no one has carefully studied the possible link ... Dr. Christina A. Clarke from Northern California Cancer Center in ... This virus is believed to increase the risk for the ...
... are in the pipeline to reduce risk factors of heart ... heart attacks. Dr. Carl R. Alving of the Walter Reed ... implicating various infectious agents in the development of atherosclerosis, or ... may reduce heart disease risk factors such as high cholesterol. ...
... journal Human Reproduction on Friday last, announced that a group ... of babies. , But Jacques ... the United States, denied that the children had been born ... first human babies whose genetic make-up had been artificially altered ...
Cached Medicine News:
... 4, 8, or 12 channel pipettors. Angled ... nearly all of the solution. Corners have ... Made of natural virgin polystyrene containing no ... 152 mm L x 35 mm H ...
Volume: 5 ml; Volume Graduation: 1/10 ml...
... for use with measuring pipettes, enables you to ... works with all types of glass or plastic ... to 100 mL.Gilsons Pipette Aid is equipped with ... protect the mechanism of the device from contamination ...
Application: Safe and convenient filling and dispensing of glass and plastic pipets....
Medicine Products: